Fuji Pharma Receives the MHLW Approval of AVT04 (biosimilar, ustekinumab) in Japan
Shots:
- The MHLW has approved AVT04 (ustekinumab), a biosimilar to Stelara for autoimmune conditions. AVT04 was developed using an Sp2/0 host cell line and is manufactured using a continuous perfusion process
- Alvotech and Fuji have a joint commitment to increase patient access to vital biologic medicines. Under the 2018 agreement, Alvotech is responsible for development and manufacturing and Fuji Pharma got an exclusive commercialization right in Japan
- AVT04 is a mAb and a biosimilar candidate to Stelara which binds to two cytokines, IL-12 and IL-23 involved in inflammatory and immune responses
Ref: Globenewswire | Image: Fuji Pharma
Related News:- Alvotech and Teva Settled with Johnson & Johnson for AVT04, a Proposed Biosimilar to Stelara (ustekinumab)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
